Frontlight ResearchEarly access
Not yet taking people in NorwayPhase 1/2
Tests a radioactive treatment for brain glioma that has grown or returned
Tests a radioactive drug given into an artery in adults with brain glioma.
Key facts
- Who runs it
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Where
- Trondheim, NorwaySee the siteAlso in 1 other country, 1 site
- Trial code
- Registry title
- The ALPINE trial: a phase 1-2 study of intra-arterial [177Lu]Lu-PSMA-I&T for progressive or recurrent intracranial adult type diffuse glioma
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 28 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 27 Nov 2028
- Type of study
- Interventional
- Record updated
- 13 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a brain tumour called diffuse glioma that has grown or come back.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
- Disease stage
- Diffuse glioma (diffuse astrocytoma, oligodendroglioma or glioblastoma) inside the skull that is progressing or has recurred.
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norway
Also in 1 other country, 1 site
- St. Olavs hospital HFTrondheim, NorwayNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests a radioactive treatment for brain glioma that has grown or returnedGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2023-504696-24-00, who can take part
- Record updated
- 13 May 2026